Lung Cancer
Return to Library
|
Free Lung Cancer Articles |
|
|
|
|
Studies from S. Sura and co-researchers in the area of non-small cell lung cancer published
2007 NOV 19 -- "Local failure continues to be a major cause of mortality in patients with inoperable non-small cell lung cancer (NSCLC) treated with radiation therapy. Dose escalation is one method of improving local control," scientists writing in the Cancer Journal report. "We investigated whether high-dose radiotherapy enhances outcomes in patients with inoperable NSCLC Eighty-two patients with inoperable NSCLC stage I-IIIB were treated with three-dimensional conformal radiotherapy to doses of >= 80 Gy. Patients were divided into 2 groups based on stage: those with stage I/II disease (55 patients) and those with stage III (IIIA or IIIB) disease (27 patients) The 5-year local control and overall survival rates for the patients with stage I/II disease were 67% and 36%, respectively, with a median survival time of 41 months. For the patients with stage III disease, 5-year local control and overall survival rates were observed to be 39% and 31%, respectively, with a median survival time of 32 months Our data show a favorable 5-year overall survival rate (36%) with an acceptable toxicity profile in patients with early-stage NSCLC treated to doses of >= 80 Gy using three-dimensional conformal radiotherapy. Sequential chemotherapy combined with high-dose radiation gave survival rates equivalent to those seen with concurrent chemoradiation therapy in locally advanced disease," wrote S. Sura and colleagues. The researchers concluded: "The overall survival and local control rates observed among patients with all stages of disease are consistent with and comparable to results from other dose-escalation studies reported in the literature." Sura and colleagues published their study in Cancer Journal (High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer. Cancer Journal, 2007;13(4):238-242). Additional information can be obtained by contacting K.E. Rosenzweig, Mem Sloan Kettering Cancer Center, Dept. of Radiation Oncology, 1275 York Avenue, New York City, NY 10021, USA. The publisher of the Cancer Journal can be contacted at: Jones and Bartlett Publishers, 40 Tall Pine Dr., Sudbury, MA 01776, USA. Keywords: United States, New York, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Oncology. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2007, Clinical Oncology Week via NewsRx.com.
|
